Development and validation of a high‐performance liquid chromatography–tandem mass spectrometric method for simultaneous determination of bupropion,quetiapine and escitalopram in human plasma |
| |
Authors: | Semin Park Chul‐Soo Park Sung Joong Lee Boseok Cha Young Ah Cho Yi Song Eun Ae Yu Gon‐Sup Kim Jong Sung Jin A M Abd El‐Aty H A El‐Banna Ahmet Hac?müftüo?lu Jae‐Han Shim Sung Chul Shin |
| |
Affiliation: | 1. Research Institute of Life Science and Department of Chemistry, Gyeongsang National University, Jinju, Republic of Korea;2. Department of Psychiatry, Gyeongsang National University College of Medicine, Jinju, Republic of Korea;3. Research Institute of Life Science and College of Veterinary Medicine, Gyeongsang National University, Jinju, Republic of Korea;4. Division of High Technology Materials Research, Busan Center, Korea Basic Science Institute, Busan, Republic of Korea;5. Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt;6. Biotechnology Research Institute, College of Agriculture and Life Science, Chonnam National University, Gwangju, Republic of Korea;7. Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum, Turkey |
| |
Abstract: | In the present study, an effective high performance liquid chromatography–tandem mass spectrometric (HPLC/MS/MS) method was developed and validated to simultaneously determine bupropion (BUP), quetiapine (QUE) and escitalopram (ESC) in human plasma using carbidopa as the internal standard. Chromatographic separation was achieved on a Waters Sun Fire C18 column using reversed‐phase chromatography. The MS/MS experiment was performed in positive ion multiple reaction monitoring mode to produce product ions of m/z 240.3 → 184.2 for BUP, 384.2 → 253.1 for QUE, 325.3 → 109.3 for ESC and 227.2 → 181.2 for the internal standard. The method showed good linearity (R2 ≥ 0.997), precision (relative standard deviation ≤7.5%), satisfactory intra‐ and interday accuracy (88.4–113.0%) and acceptable extraction recovery (87.2–115.0%), matrix effect (84.5.5?108.7%) and stability (92.3?103.5%). The method was successfully applied to determine the concentrations of BUP, QUE and ESC in human plasma samples. Copyright © 2014 John Wiley & Sons, Ltd. |
| |
Keywords: | major depressive disorder bupropion quetiapine escitalopram LC/MS/MS |
|
|